Moleculin Biotech's Annamycin Cardiac Safety Data Accepted for ASCO Presentation
MBRX sits 34% above its 52-week low of $1.79.
Summary
Moleculin Biotech announced that strong cardiac safety data for its lead drug candidate, Annamycin, has been accepted for presentation at the upcoming ASCO Annual Meeting, reinforcing its potential as a safer anthracycline.
Key Events · Product Development and Regulatory · MBRX
-
ASCO Abstract Acceptance
An abstract featuring pooled cardiac safety data for Annamycin has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026).
-
Strong Cardiac Safety Profile
Pooled analysis from 90 patients across five trials showed no statistically significant change in Left Ventricular Ejection Fraction (LVEF) and no evidence of drug-induced cardiotoxicity, even at cumulative doses exceeding conventional lifetime anthracycline limits.
-
Addresses Key Treatment Barrier
This data supports Annamycin's potential to provide effective anthracycline therapy without the traditional cumulative dose limitations associated with cardiotoxicity, a major issue for existing chemotherapies.
-
Supports Pivotal Trial
The positive safety findings further strengthen the rationale for the company's ongoing pivotal Phase 2b/3 MIRACLE trial in patients with relapsed or refractory acute myeloid leukemia (AML).
Analysis · MBRX · Life Sciences
This filing announces the acceptance of strong cardiac safety data for Annamycin, Moleculin Biotech's lead drug candidate, for presentation at the prestigious ASCO Annual Meeting. The data, showing no significant cardiotoxicity even at high cumulative doses, is critical because cardiotoxicity is a major limiting factor for conventional anthracycline chemotherapy. For a company facing a 'going concern' warning and needing significant capital, this positive clinical validation for its pivotal Phase 2b/3 trial strengthens the investment thesis and could be crucial for future financing efforts.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $1.79 to $24.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.